Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.24 USD

39.24
1,175,687

-0.71 (-1.78%)

Updated Oct 1, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ImmunoGen (IMGN) Files BLA for Lead Drug in Ovarian Cancer

by Zacks Equity Research

ImmunoGen (IMGN) seeks accelerated approval from the FDA for its lead candidate, mirvetuximab soravtansine, in previously treated platinum-resistant ovarian cancer. This pushes the stock price up.

Roche (RHHBY) Late-Stage Study for ES-SCLC Fails to Meet Goal

by Zacks Equity Research

Roche (RHHBY) phase III SKYSCRAPER-02 study assessing tiragolumab plus Tecentriq and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer did not meet co-primary endpoint of progression-free survival.

JAZZ Initiates Zepzelca Basket Study in Advanced Solid Tumors

by Zacks Equity Research

JAZZ enrolls the first patient in a mid-stage study to evaluate its lung cancer drug, Zepzelca, in advanced and difficult-to-treat cancer indications in previously-treated patients.

Halozyme (HALO) Inks Collaboration Deal With Chugai Pharma

by Zacks Equity Research

Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.

Amgen (AMGN) Outperforms Industry This Year So Far: What Next?

by Zacks Equity Research

Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why

by Zacks Equity Research

Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang.

Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

by Zacks Equity Research

Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.

Exelixis (EXEL) Announces Final Results From HCC Study

by Zacks Equity Research

Exelixis (EXEL) does not intend to submit a supplemental new drug application to the FDA for Cabometyx in patients with previously untreated advanced hepatocellular carcinoma.

AbbVie (ABBV) Inks Deal for Neuropsychiatric Conditions

by Zacks Equity Research

AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar.

Sanofi's (SNY) Hemophilia A Candidate Meets Study Endpoints

by Zacks Equity Research

Sanofi (SNY) and Sobi's factor VIII replacement therapy candidate, efanesoctocog alfa, achieves clinically meaningful prevention of bleeds in people with severe hemophilia A

Adaptive Biotechnologies (ADPT) Rises on Restructuring Plans

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) announces reorganization of its business around MRD and Immune Medicine to drive future growth. The company hires a market veteran in health care as its new CFO.

    AbbVie (ABBV) Outperforms Industry This Year So Far: What Next?

    by Zacks Equity Research

    AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

    Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag

    by Zacks Equity Research

    Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. Nevertheless, the pipeline progress is encouraging.

    Sarepta (SRPT) Q4 Earnings Beat, DMD Drugs Sales Robust

    by Zacks Equity Research

    Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the fourth quarter. The company also raises revenue guidance for the year. Stock down in after-market trading.

    ImmunoGen (IMGN) Q4 Earnings and Sales Outpace Estimates

    by Zacks Equity Research

    ImmunoGen (IMGN) reports a narrower-than-expected loss for fourth-quarter 2021. It also beats revenue estimates. Post the announcement, the share price rises.

    Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues

    by Zacks Equity Research

    Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.

    Prothena (PRTA) Q4 Earnings Beat, Pipeline Progress in Focus

    by Zacks Equity Research

    Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.

    Mark Vickery headshot

    Top Analyst Reports for Adobe, Altria Group & Marriott International

    by Mark Vickery

    Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), Altria Group, Inc. (MO), and Marriott International, Inc. (MAR).

    Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark

    by Zacks Equity Research

    Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.

    Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate

    by Zacks Equity Research

    Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.

    Amgen's (AMGN) Q4 Earnings Top Estimates, Product Sales Fall

    by Zacks Equity Research

    Amgen (AMGN) beats Q4 estimates for earnings but misses the same for sales. Higher Other Revenue for manufacturing Eli Lilly's COVID-19 antibody boost sales growth.

    Regeneron (REGN) Beats on Q4 Earnings, Gains on REGEN-COV

    by Zacks Equity Research

    Regeneron (REGN) Q4 earnings beat estimates and sales record strong year-over-year growth on the solid performance of REGEN-COV as well as Eylea and Dupixent.

    Biogen (BIIB) Q4 Earnings Top, Stock Down on Weak 2022 View

    by Zacks Equity Research

    Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The stock declines on weak sales and earnings guidance for 2022.

    Roche's (RHHBY) 2021 Earnings, Sales Grow on COVID-19 Tests

    by Zacks Equity Research

    Roche (RHHBY) performance in the fourth quarter and 2021 was encouraging, driven by demand for COVID-19 tests and recovery in pharma sales. However, sales are expected to slow down in 2022.

    Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing

    by Zacks Equity Research

    Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.